When will Xtampza ER lose exclusivity and be eligible for generic entry?
Xtampza ER (oxycodone extended-release) is protected not just by a single patent, but by a bundle of exclusivities and patents that can delay generic approval. The exact time depends on which protection is still in force for the specific formulation and any patent challenges tied to the drug product.
Because you didn’t include the country (U.S., EU, etc.) or which Xtampza strength you mean, I can’t calculate a definitive “how many years” timeline from the information provided here.
What determines the “generic date” for Xtampza in the U.S.?
In the U.S., generic or “AB-rated” versions typically line up with the end of:
- FDA marketing exclusivity (a regulatory exclusivity clock), and/or
- the last-to-expire relevant patents listed for Xtampza ER in the FDA Orange Book (a patent clock), including any extensions and “pediatric exclusivity” effects if applicable.
Generic applicants can file before those dates (via ANDA), but approval is generally blocked until the relevant exclusivities/patents expire or are cleared through litigation.
Can a generic launch before the last patent expires?
Yes, but only if the generic applicant wins the patent fight for the relevant patents or the remaining patents are found not to block approval. Even then, timing can still be constrained by how FDA ties each listed patent to the proposed generic product.
If you’re looking for a practical answer like “the earliest likely generic launch,” that requires knowing the specific Orange Book entries for Xtampza ER (by strength and listed active ingredient) and the status of related litigation.
Which details should you share so I can give you the exact timeline?
If you tell me:
1) the country (most people mean the U.S.),
2) the strength (e.g., 9 mg, 13.5 mg, 18 mg, 27 mg, 36 mg), and
3) whether you mean “generic approval” or “generic availability in pharmacies,”
I can pinpoint the relevant exclusivity/patent expiry targets for that specific product and estimate the time to first generic launch.
Quick check: do you mean Xtampza ER specifically, or oxycodone ER generally?
Xtampza is a specific branded, abuse-deterrent oxycodone extended-release product. Generic oxycodone ER products may exist, but they are not necessarily interchangeable with Xtampza’s specific formulation if FDA labeling/interchangeability differs. That affects what patients and prescribers mean by “becomes generic.”
---
If you want, reply with “U.S.” and the Xtampza strength you take (or the one you’re researching), and I’ll give the most direct timeline for when generic competition can begin.